Overall, droperidol sedates faster and more cleanly than haloperidol or lorazepam, either alone or in combination. Data support not obtaining screening ECGs and continuous cardiovascular monitoring is not required. Droperidol was, in years past, the first-line therapy for sedation; the time has come for it to return to that status.
Explore This IssueACEP Now: Vol 38 – No 09 – September 2019
Dr. Boyer is director of research and academic development at Brigham and Women’s Hospital and associate professor of emergency medicine at Harvard Medical School in Boston.
- Perkins J, Ho JD, Vilke GM, et al. American Academy of Emergency Medicine position statement: safety of droperidol use in the emergency department. J Emerg Med. 2015;49(1):91-97.
- Martel M, Sterzinger A, Miner J, et al. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med. 2005;12(12):1167-1172.
- Isbister GK, Calver LA, Page CB, et al. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med. 2010;56(4):392-401.e1.
- Calver L, Page CB, Downes MA, et al. The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department. Ann Emerg Med. 2015;66(3):230-238.e1.
- Richards JR, Derlet RW, Duncan DR. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med. 1998;16(4):567-573.